Search
Cabazitaxel
go.drugbank.com/drugs/DB06772ApprovedInvestigational[A7056] Due to its low affinity for the P-glycoprotein (P-gp) efflux pump, cabazitaxel can more readily penetrate the blood–brain barrier compared to other taxanes like [paclitaxel] and [docetaxel]. … [A7056, A260421, A260621] Cabazitaxel is used to treat metastatic castration-resistant prostate cancer. It was first approved by the FDA on June 17, 2010.
Products: JEVTANA 60MG/1,5ML INFÜZYONLUK KONSANTRE ÇÖZELTI VE ÇÖZÜCÜ, 1 ADET VE 1 ÇÖZÜCÜTapinarof
go.drugbank.com/drugs/DB06083ApprovedInvestigationalIt is available as a topical cream to be applied to the affected area once daily. … [A248790] Tapinarof received initial approval from the FDA in 2022.[L41845]
Categories: Aryl Hydrocarbon Receptor AgonistHexafluronium
go.drugbank.com/drugs/DB00941ApprovedIt is known to bind and block the activity of plasma cholinesterases. … Hexafluronium bromide is a neuromuscular blocking agent used in anesthesiology to prolong and potentiate the skeletal muscle relaxing action of suxamethonium during surgery.
Obinutuzumab
go.drugbank.com/drugs/DB08935ApprovedInvestigational[L54521] Like other drugs in its class, obinutuzumab targets the CD20 antigen expressed on the surface of pre-B and mature B lymphocytes, mediating B-cell lysis. … [L54521] First approved by the FDA on February 26, 2016,[L54531] obinutuzumab is used to treat chronic lymphocytic leukemia, follicular lymphoma, and lupus nephritis.[L54521]
Thioproperazine
go.drugbank.com/drugs/DB01622ApprovedIt is used for the treatment of all types of acute and chronic schizophrenia, including those which did not respond to the usual neuroleptics; manic syndromes.
Categories: Adrenergic alpha-1 Receptor Antagonists, Dopamine D2 Receptor AntagonistsLindane
go.drugbank.com/drugs/DB00431ApprovedWithdrawnLindane has been banned in California, United Kingdom, Australia, and many western countries due to concerns about neurotoxicity and adverse effects on the environment. … In Canada, Lindane is not recommmended as a first-line therapy due to reports of resistance, neurotoxicity, and bone marrow suppression, but has been approved by the FDA as a second-line therapy for topical
Triheptanoin
go.drugbank.com/drugs/DB11677ApprovedInvestigationalTriheptanoin is a source of heptanoate fatty acids, which can be metabolized without the enzymes of long chain fatty acid oxidation. … [A214812,A214817] Complications in lc-FAOD patients are reduced from approximately 60% to approximately 10% with the addition of triheptanoin.
Ropinirole
go.drugbank.com/drugs/DB00268ApprovedInvestigationalIn 2005, it was the first drug approved in the US for the management of primary moderate to severe restless legs syndrome [A174547]. … Ropinirole was initially approved in 1997 by the FDA [FDA label] for the management of Parkinson's disease.
Categories: Nonergot-derivative Dopamine Receptor AgonistsDiosmin
go.drugbank.com/drugs/DB08995ApprovedInvestigationalChronic venous insufficiency is a common condition the western population. … Diosmin is widely available over-the-counter and demonstrates a favourable a favorable safety profile.[A232890,T840,L33040]
Paltusotine
go.drugbank.com/drugs/DB16277ApprovedInvestigationalPaltusotine is a selective somatostatin receptor agonist: It mimics the biological actions of endogenous somatostatin, which activates the somatostatin 2 receptor (SST2) to block the secretion of growth … [A274476] Paltusotine was approved by the FDA on September 25, 2025 for the treatment of acromegaly in adults.[L54061]
Categories: Somatostatin Receptor Agonists